pcDNA3.1‐GATA5 was constructed as follows. Full‐length human GATA5 cDNA (residue 1‐397, NCBI: NM_080473) was synthesized with a Kozak sequence GCCACC at the N‐terminus. Then, the synthetic cDNA was amplified by PCR using the following primer pairs: 5′CCG
AAGCTTGCCACCATGTACCAGAGCCT‐3′ and 5′‐CGG
GCGGCCGCCTAGGCCAAGGCCAGCGC‐3′. The
HindIII and
NotI restriction sites are underlined. The PCR product was digested with
HindIII and
NotI restriction enzymes (Takara Bio Inc, China) and ligated into the expression vector
pcDNA3.1(+) (Invitrogen, USA). The stable expression vector CDH‐GATA5 construct was similar to the pcDNA3.1‐GATA5. The difference between them was that the CDH‐GATA5 vector colony was cloned into the pCDH‐CMV‐MCS‐EF1‐coGFP plasmid (SystemBio, USA) using restriction enzymes
BamHI/
EcoRI (Takara Bio Inc, China). The expression vector was transformed into
Escherichia coli and used for amplification.
The transfection of GATA5 expression vectors into HCC cells was induced by
Lipofectamine 2000 (Invitrogen). For stable expression vectors CDH‐GATA5, 400 mg/mL G418 was applied to screen stable cell clones, and the transfection of HLE, Bel7402 and PLC/PRF/5 cells was termed HLE‐GATA5, Bel7402‐GATA5 and PLC/PRF/5‐GATA5.
Feng H., Zhu M., Zhang R., Wang Q., Li W., Dong X., Chen Y., Lu Y., Liu K., Lin B., Guo J, & Li M. (2019). GATA5 inhibits hepatocellular carcinoma cells malignant behaviours by blocking expression of reprogramming genes. Journal of Cellular and Molecular Medicine, 23(4), 2536-2548.